It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...

Among patients with type 2 diabetes, use of GLP-1 agonists may increase the risks for adhesive capsulitis and required ...

Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders of pregnancy, gestational diabetes, have a preterm birth or cesarean ...

Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...

A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!

A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug ...

The EMA’s safety committee has said that, after a review of available data, it has found no evidence that GLP-1 agonist drugs such as Novo Nordisk’s Ozempic and Eli Lilly’s Trulicity can ...

Glucagon-like peptide-1 receptor agonist medications for weight loss are significantly transforming the field of facial plastic surgery.

The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity. HealthDay News — The glucagon-like peptide-1 receptor agonist exenatide ...

PAA Plains All American Pipeline, L.P.